Anika Therapeutics | ANIK - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Abbott USD 18.38B 1.88B 2026-03
Agenus USD 249.24M 74.25M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Integra LifeSciences USD 346.85M 109.14M 2026-03
Intrexon USD 23.02M 38K 2024-06
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Ligand Pharmaceuticals USD 40.67M 3.22M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Merit Medical Systems USD 216.87M 22.89M 2026-03
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Smith & Nephew USD 1.54B 236M 2025-12
Stryker USD 6.32B 1.48B 2026-03
Veracyte USD 56.11M 3.82M 2026-03
Xencor USD 73.46M 22.45M 2026-03
Zimmer Biomet Holdings USD 2.86B 280.6M 2026-03